Bould Opportunities PLC Stock price




Construction Supplies & Fixtures

Delayed London Stock Exchange 02:30:01 2019-10-07 am EDT Intraday chart for Bould Opportunities PLC 5-day change 1st Jan Change
0.023 GBX -.--% +24.32% +43.75%
Sales 2020 * - Sales 2021 * - Capitalization 5.71K 7.16K
Net income 2020 - 0 Net income 2021 * - EV / Sales 2020
Net cash position 2020 84K 105K Net cash position 2021 * - 0 EV / Sales 2021 * -
P/E ratio 2020
P/E ratio 2021 *
Employees -
Yield 2020
Yield 2021 *
Free-Float 56.34%
More Fundamentals * Assessed data
Dynamic Chart
Cizzle Biotechnology Holdings PLC is a United Kingdom-based diagnostics developer company engaged in developing a blood test for the early detection of the different forms of lung cancer. The Company's proof-of-concept prototype test is based on the ability to detect a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. It helps to reduce the need for repeated computed tomography (CT) scanning. The Company provides its product AZD1656 is treatment for COVID19 patients. AZD1656 is an immunomodulator which damps down the inflammatory response characteristic of coronavirus disease (COVID-19) infection, while enhancing the part of the immune response. The Company has developed a prototype confirmative test to address the false positive rates of CT scanning to avoid unnecessary invasive testing.
More about the company
  1. Stock
  2. Equities
  3. Stock Bould Opportunities PLC - London Stock Exchange
As early as today, start finding the best investment opportunities!
Optimize my profits